Join Growin Stock Community!

Molecular partners agMOLN.US Overview

US StockHealthcare
(No presentation for MOLN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MOLN AI Insights

MOLN Overall Performance

MOLN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MOLN Recent Performance

6.97%

Molecular partners ag

0.05%

Avg of Sector

-0.31%

S&P500

MOLN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MOLN Key Information

MOLN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MOLN Profile

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Price of MOLN

MOLN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MOLN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.61
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
199.56
PB Ratio
1.52
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-9515.86%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.61
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
199.56
PB Ratio
1.52
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-9515.86%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is MOLN's latest earnings report released?

    The most recent financial report for Molecular partners ag (MOLN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MOLN's short-term business performance and financial health. For the latest updates on MOLN's earnings releases, visit this page regularly.

  • How is MOLN's revenue growth?

    In the latest financial report, Molecular partners ag (MOLN) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MOLN have?

    As of the end of the reporting period, Molecular partners ag (MOLN) had total debt of 1.53M, with a debt ratio of 0.01. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MOLN have?

    At the end of the period, Molecular partners ag (MOLN) held Total Cash and Cash Equivalents of 82.36M, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MOLN's EPS continuing to grow?

    According to the past four quarterly reports, Molecular partners ag (MOLN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MOLN?

    Molecular partners ag (MOLN)'s Free Cash Flow (FCF) for the period is -9.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 26.46% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MOLN?

    The latest valuation data shows Molecular partners ag (MOLN) has a Price-To-Earnings (PE) ratio of -1.9 and a Price/Earnings-To-Growth (PEG) ratio of 0.06. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.